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ARTICLE
Reversibility of Apixaban Anticoagulation with
a Four-Factor Prothrombin Complex Concentrate
in Healthy Volunteers
S Nagalla1, L Thomson2, Y Oppong3, B Bachman1, I Chervoneva3 and WK Kraft3,∗
It was hypothesized that the four-factor prothrombin complex concentrate (4F-PCC) Kcentra 25 unit/kg would reverse impair-
ment of thrombin generation in healthy volunteers dosed with apixaban to steady state. In this randomized, two-period
crossover, assessor-blinded trial, 12 healthy subjects received 5 mg apixaban every 12 h. Three h after the fifth dose, four-
factor prothrombin complex concentrate (4F-PCC) 25 unit/kg or saline were infused. Serial blood samples were assessed for
thrombin generation using PPP-reagent and PPP-reagent low, anti-Xa, PT, and PTT assays. Geometric mean ratio was calculated
at 30 min postinfusion, and at 24, 48, and 72 h. Peak thrombin generation was 76% higher at 30 min postinfusion with 4F-PCC
(p = 0.025). The difference declined to 24% at 24 h and resolved by 48 h. Other thrombin generation parameters were also
partially normalized. There was no difference between 4F-PCC and saline in anti-Xa assessment at 30 min or later time points.
Clin Transl Sci (2016) 9, 176–180; doi:10.1111/cts.12398; published online on 12 May 2016.
Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?
✔ Apixaban is a commonly used anticoagulant without
a reliable reversal agent in circumstances of acute bleed-
ing. Factor prothrombin concentrate complex products are
sometimes used off label in this clinical situation.
WHAT QUESTION DID THIS STUDY ADDRESS?
✔ The study sought to evaluate if a four-factor prothrombin
concentrate complex would improve thrombin generation
in humans dosed to steady state with apixaban.
WHAT THIS STUDY ADDS TO OUR KNOWLEDGE?
✔ The four-factor prothrombin concentrate complex
Kcentra improves thrombin generation parameters com-
pared with placebo.
HOW THIS MIGHT CHANGE CLINICAL PHARMACOL-
OGY OR TRANSLATIONAL SCIENCE?
✔ This proof of concept finding provides evidence of
improvement in hemostatic potential in patients with apix-
aban use and bleeding.
For more than 50 years, the only class of oral anticoagu-
lants available had been the vitamin K antagonists (VKAs),
such as warfarin.1,2 The direct factor Xa inhibitors apixaban,
edoxaban, and rivaroxaban are now clinical options.3,4 These
agents have been shown to be as effective or superior to
VKAs in preventing thrombotic events and offer several ben-
efits over the VKAs, which include more predictable pharma-
cokinetics and pharmacodynamics and fewer food and drug
interactions.3–5 Unlike the VKAs, however, there are no estab-
lished reversal agents in cases of emergent bleeding for Xa
inhibitors.6
Preclinical trials have suggested that prothrombin complex
concentrates can reverse the anticoagulant effects caused
by factor Xa inhibition. Clinical trials evaluating this effect,
however, are scarce. Eerenberg et al.7 demonstrated par-
tial reversal of anticoagulant effects of the factor Xa inhibitor
rivaroxaban by the nonactivated four-factor prothrombin
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complex concentrate (4F-PCC) Cofact. In an in vitro study,
Escolar et al.8 showed that PCCs have the potential to
restore fibrin components of hemostasis previously altered
by apixaban. Cofact may be partially beneficial in the rever-
sal of the anticoagulant effect of apixaban. Kcentra cur-
rently is the only nonactivated 4F-PCC available in the United
States, and could potentially have some activity against apix-
aban induced anticoagulation, but has not been system-
atically evaluated. We studied the effect of Kcentra at the
dose of 25 unit/Kg in reversing the anticoagulant effects of
therapeutic dose apixaban (5 mg twice daily) in 12 healthy
subjects.
METHODS
Study design
This was a phase I, investigator-initiated, placebo-controlled,
single site, open-label, assessor blinded, crossover trial to
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Figure 1 Study design schema.
evaluate the reversibility of the anticoagulant effects of apix-
aban by Kcentra. The study was approved by the Institutional
Review Board of Thomas Jefferson University and registered
with Clinicaltrials.gov (NCT 02270918). All enrolled subjects
received 5 mg of oral apixaban every 12 h (Q12) for two and a
half days. Subjects were randomized to receive either Kcen-
tra 25 unit/kg or placebo in the form of normal saline solu-
tion intravenously 3 h after the last apixaban dose. Kcen-
tra was infused at a rate of 0.12 mL/kg/min, with a similar
duration for matched placebo saline. Blood was collected
for analysis of thrombin generation, anti-factor Xa (anti-Xa)
activity, prothrombin time (PT) and activated partial throm-
boplastin time (PTT). Blood collection took place at screen-
ing and before administration of the last dose of apixa-
ban and at 1, 2, 3 (time of Kcentra/placebo infusion), 3.75
(30 min postinfusion), 4.25, 5, 6, 8, 10, 12, 24, and 72 h post-
apixaban administration. Subjects had a washout period
of 10 days and then crossed over to the other treatment
arm after another two and a half days of apixaban dosing
(Figure 1). Blood for study outcome measures was frozen
and stored at −70 C until processing. Staff performing all
laboratory assessments were blinded to the treatment allo-
cations. Thrombin generation was performed on a Throm-
binoscope (Stago). Anti-Xa analysis was performed using an
ACL TOP 500 instrument (Instrumentation Laboratory).
Statistical methods
Study end points are presented in Table 1. It was antici-
pated that the administration of apixaban 5 mg Q12 h (esti-
mated in vivo concentration of approximately 0.2 uM) would
reduce peak thrombin generation from 250 nM to 50 nM at
30 min postinfusion.9 The sample size of 12 subjects was
calculated to provide 80% power to detect the effect size
of 0.89 (mean difference of 0.89 if the SD of the differences
is 1, using paired t test with alpha 0.05). To investigate the
carryover and period effects, the peak thrombin generation
measures at 3 and 3.75 h after apixaban dosing (correspond-
ing to before and 30 min postinfusion) in each period were
modeled using linear mixed effects (LMEs) models with treat-
ment group, period, and sequence as fixed effects. Statistical
significance of the period effects and carryover (sequence
effect) was tested using model-based type III tests of the
fixed effects with Kenward & Rodger10 estimated denomi-
nator degrees of freedom. The effectiveness of washout was
evaluated by testing the difference between day -1 and day
13 (corresponding to the day before dosing with apixaban
was initiated in each period) using LME model-based paired
t test with alpha 0.05. The residuals and best linear unbi-
ased predictors from all fitted LME models were evaluated
Table 1 Study end points
Assay Reagent Time point
Primary
end point
Peak thrombin
generation
PPP-reagent low
(Stago)
30 min after
Kcentra/placebo
infusion
Secondary
end points
Thrombin generation
1. Peak thrombin
generation
(0–72 h only);
2. Endogenous
thrombin
potential;
3. Lag time;
4. Time to peak
thrombin
generation;
5. mVRI.
PPP-reagent low
PPP-reagent
(Stago)
30 min after Kcentra/
placebo infusion
and 0–72 h
Chromogenic
anti-factor Xa
Biophen Heparin
(Anaria)
PT PT reagent
(Instrumentation
Laboratory)
PTT APTT reagent
(Instrumentation
Laboratory)
mVRI, mean velocity rate index; PT, prothrombin time; PTT, partial thrombo-
plastin time.
for adequacy of the normal distribution assumptions. The
time trends in all repeated measures of anticoagulation from
time 0 to 72 h were evaluated descriptively. The anticoagu-
lation measured at later times was analyzed in separate LME
models with the nominal fixed effect of treatment, time and
their interaction. Based on these models, the treatment dif-
ferences at 24, 48, and 72 h were evaluated. Multiple testing
adjustments were not implemented because of the use of a
single a priori primary end point and the congruency of meth-
ods and biologic mechanisms for the secondary end points.
RESULTS
Twelve nonsmoking healthy male (n = 11) or female (n = 1)
subjects were enrolled. The mean age was 46 years (range,
36–51 years), weight 83 kg (range, 60–97 kg), and body mass
index was 27 kg/m2 (range, 23–32 kg/m2). All subjects were
in good health and had normal platelet counts and base-
line coagulation parameters. No subjects used nonsteroidal
anti-inflammatory drugs or other antiplatelet agents, herbal
products, or other prescription or over the counter medica-
tions. There were no serious adverse effects and all treat-
ments were well tolerated. Thrombin generation geometric
www.wileyonlinelibrary/cts
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Table 2 Thrombin generation geometric mean ratio end points 30 min after
infusion of Kcentra or placebo
Reagent Measure
Kcentra/
placebo
GMR
Lower
95% CI
Upper
95% CI p value
PPP low Peak thrombin
generation
1.76 1.09 2.83 0.025
PPP Peak thrombin
generation
1.76 1.19 2.60 0.009
PPP low Endogenous thrombin
potential
1.53 0.92 2.54 0.091
PPP Endogenous thrombin
potential
1.49 1.02 2.20 0.042
PPP low Lag time 0.73 0.61 0.86 0.002
PPP Lag time 0.72 0.62 0.85 0.001
PPP low Time to peak
thrombin generation
0.80 0.64 1.00 0.050
PPP Time to peak
thrombin generation
0.89 0.70 1.13 0.305
PPP low mVRI 1.78 0.83 3.80 0.124
PPP mVRI 1.62 0.91 2.89 0.094
CI, confidence interval; GMR, geometric mean ratio; mVRI, mean velocity rate
index.
Table 3 Anti-Xa, PT, PTT 30 min after infusion of Kcentra or placebo
Measure
Kcentra/ placebo
GMR Lower 95% CI Upper 95% CI p value
Anti-Xa 0.98 0.82 1.16 0.761
PT 0.85 0.80 0.91 <0.001
PTT 1.01 0.91 1.11 0.880
CI, confidence interval; GMR, geometric mean ratio; PT, prothrombin time;
PTT, partial thromboplastin time.
mean ratio end points 30 min after infusion of Kcentra or
placebo are presented in Table 2. Kcentra infusion increased
peak thrombin generation by 76% at 30 min postinfusion
with both PPP-reagent low and PPP-reagent. PPP-reagent
is a mixture of phospholipids and tissue factor. PPP-reagent
low is a mixture of phospholipids with a low level of tissue
factor. Partial reversal of apixaban effect was also demon-
strated by increased endogenous thrombin potential, as well
as decreased lag time and time to peak thrombin genera-
tion. Mean velocity rate index was increased, but there was
not a statistically significant difference between treatments.
At 30min post-Kcentra or placebo infusion, there were no dif-
ferences in anti-Xa or PTT values (Table 3). There was a sta-
tistically significant shortening of the PT, although all values
were within the normal limits. By 24 h, there was largely no
difference between the groups (Table 4). With the excep-
tion of peak thrombin generation and endogenous throm-
bin potential, thrombin generation parameters were gener-
ally similar between groups by 24 h (Table 5), and began to
approach baseline (prestudy) values.
DISCUSSION
Results demonstrate that 25 unit/kg Kcentra reversed the
anticoagulant effect of apixaban 5 mg twice daily in healthy
human volunteers. The primary end point of the study, peak
thrombin generation, increased significantly after treatment
Table 4 Anti-Xa, PT, and PTT at 24, 48, and 72 h
Measure
Time
point
Kcentra/
placebo
GMR
Lower
95% CI
Upper
95% CI p value
Anti-Xa 24 0.94 0.75 1.19 0.615
Anti-Xa 48 0.89 0.71 1.12 0.315
Anti-Xa 72 0.90 0.71 1.13 0.348
PTT 24 1.01 0.96 1.06 0.632
PTT 48 1.04 0.99 1.09 0.100
PTT 72 1.03 0.98 1.09 0.179
PT 24 0.97 0.95 0.99 0.019
PT 48 1.00 0.98 1.03 0.782
PT 72 1.00 0.97 1.02 0.859
CI, confidence interval; GMR, geometric mean ratio; PT, prothrombin time;
PTT, partial thromboplastin time.
with Kcentra compared with placebo. This finding was con-
sistent in both standard (PPP-reagent) and low tissue fac-
tor (PPP-reagent low) conditions. There was also immediate
improvement in the other thrombin generation parameters.
Although the optimal level of thrombin generation potential to
prevent clinically impactful bleeding is not well defined, our
study suggests that Kcentra may be an effective treatment
option for a patient on apixaban with moderate to severe and
life-threatening bleeding.
Although Kcentra caused a statistically significant
decrease in PT compared with placebo, the pre-Kcentra
treatment samples had a normal PT value in the presence of
apixaban. There were no statistically significant differences
in the PTT and anti-Xa levels. These results demonstrate
the lack of usefulness of these tests in discerning the
amount of drugs in vivo. Newer anti-Xa assays (Biophen
DiXAL) have recently become commercially available that
are designed specifically for measurement of the activity of
oral anti-Xa inhibitors with relative insensitivity to heparin
concentrations up to 2 unit/mL, and may be more reliable
than the anti-Xa assay (Biophen Heparin) available at the
time of this study. The thrombin generation assay may not
be readily available in all hospitals. These findings stress the
importance of not relying on the use of PT, PTT, or anti-Xa
assays for the decision-making process as to whether
or not to use prothrombin complex concentrates to treat
apixaban-associated bleeding.
Cheung et al.11 reported another use of an unactivated
4F-PCC (Cofact administered at doses of 25 unit/kg and
37.5 unit/kg) for reversal of anticoagulant effects of apixa-
ban. This study used endogenous thrombin potential (ETP)
as their primary end point and demonstrated that Cofact
was able to partially reverse the anticoagulant effects of a
supratherapeutic dosage regimen of apixaban 10 mg twice
daily. We are the first to study the effect of Kcentra, the
only commercially available 4F-PCC in the United States,
on reversing the anticoagulant effects of apixaban. Although
there are some minor differences between the various avail-
able 4F-PCCs, their efficacy is most likely similar for treat-
ment purposes.12 Our study had 12 subjects compared with
the Cofact study, which had six subjects and our primary
end point was peak thrombin generation instead of ETP.
Patients on standard doses of apixaban would likely have
Clinical and Translational Science
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Table 5 Thrombin generation parameters at 24, 48, and 72 h
Reagent Measure Hour
Kcentra/ Placebo
GMR Lower 95% CI Upper 95% CI p-value
PPP low Peak thrombin generation 24 1.24 0.87 1.77 0.239
PPP low Peak thrombin generation 48 0.88 0.62 1.26 0.476
PPP low Peak thrombin generation 72 0.71 0.50 1.02 0.065
PPP Peak thrombin generation 24 1.24 1.08 1.42 0.003
PPP Peak thrombin generation 48 1.09 0.95 1.25 0.210
PPP Peak thrombin generation 72 1.03 0.90 1.18 0.677
PPP low ETP 24 1.28 1.01 1.62 0.041
PPP low ETP 48 0.96 0.76 1.22 0.740
PPP low ETP 72 0.81 0.64 1.03 0.080
PPP ETP 24 1.32 1.23 1.41 <0.001
PPP ETP 48 1.20 1.12 1.28 <0.001
PPP ETP 72 1.11 1.04 1.18 0.003
PPP low Lag time 24 1.08 0.97 1.21 0.168
PPP low Lag time 48 1.11 0.99 1.24 0.070
PPP low Lag time 72 1.07 0.96 1.20 0.232
PPP Lag time 24 1.02 0.93 1.11 0.725
PPP Lag time 48 1.06 0.98 1.16 0.150
PPP Lag time 72 1.01 0.93 1.11 0.733
PPP low Time to peak thrombin generation 24 1.06 0.98 1.15 0.117
PPP low Time to peak thrombin generation 48 1.11 1.03 1.20 0.008
PPP low Time to peak thrombin generation 72 1.09 1.01 1.18 0.030
PPP Time to peak thrombin generation 24 1.04 0.98 1.10 0.184
PPP Time to peak thrombin generation 48 1.07 1.01 1.13 0.018
PPP Time to peak thrombin generation 72 1.02 0.97 1.08 0.389
PPP low mVRI 24 1.19 0.75 1.89 0.451
PPP low mVRI 48 0.80 0.50 1.27 0.335
PPP low mVRI 72 0.64 0.41 1.02 0.062
PPP mVRI 24 1.17 0.95 1.42 0.131
PPP mVRI 48 1.03 0.84 1.25 0.790
PPP mVRI 72 1.00 0.82 1.22 0.999
CI, confidence interval; ETP, endogenous thrombin potential; GMR, geometric mean ratio; mVRI, mean velocity rate index.
steady-state drug concentrations similar to the subjects
in our study; therefore, our results have clinical rele-
vance for apixaban-associated bleeding. A 76% increase
in immediate peak thrombin generation with 25 unit/kg of
Kcentra may be adequate for most moderate to severe
bleeding events, without increasing the risk of thrombo-
sis. It is important to emphasize that patients who are
taking apixaban may be at increased risk for throm-
bosis due to their underlying thrombotic condition and
excess administration of a PCC can tip the balance
toward the thrombotic spectrum and result in adverse
events.
Our study is similar to the other studies in this field in
terms of lack of assessment of clinical bleeding outcomes
in patients. Animal studies demonstrated the benefit of 4F-
PCC in apixaban-induced bleeding and in vitro studies with
apixaban spiked human plasma demonstrated the efficacy of
4F-PCC in increasing thrombin generation.8,13–15 In a recent
retrospective study, a 4F-PCC demonstrated some clinical
benefit in reducing intracranial bleeding in patients on direct
Xa inhibitors (rivaroxaban and apixaban) without any PCC-
related adverse effects.16 Our study strengthens the observa-
tionsmade byCheung et al.11 by demonstrating the benefit of
PCC administration in human subjects on apixaban. All of the
above studies suggest that using a 4F-PCC in reversing the
anticoagulant effects of apixaban in a bleeding patient may
be a reasonable option. Based on our study results, wewould
recommend starting with a dose of 25 unit/kg of Kcentra to
treat a moderate to severe life-threatening bleeding event in
a patient on an apixaban regimen of 5 mg or 2.5 mg twice
daily with close monitoring to determine clinical response.
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